Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NRIX · as of Mar 31, 2025
Ownership Breakdown
172
Institutional Holders
▼ 7 vs Q4
$1.01B
Total Inst. Value
▼ $522.95M vs Q4
86.67M
Shares Outstanding
freeFloat 99.99%
84.60M
13F Shares Held
▲ 3.48M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NRIX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 10.33M | 12.36% | 12.36% | $122.75B | May 12, 2025 | ▼ 302.0K |
BLACKROCK, INC. pharmaceutical preparations | 7.99M | 9.56% | 9.56% | $94.87B | May 2, 2025 | ▲ 310.2K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 5.50M | 6.58% | 6.58% | $65.34B | May 15, 2025 | ▲ 2.50M |
VANGUARD GROUP INC pharmaceutical preparations | 4.42M | 5.28% | 5.28% | $52.45B | May 9, 2025 | ▲ 69.9K |
REDMILE GROUP, LLC pharmaceutical preparations | 4.05M | 4.85% | 4.85% | $48.14B | May 15, 2025 | ▼ 140.7K |
COMMODORE CAPITAL LP pharmaceutical preparations | 3.98M | 4.76% | 4.76% | $47.27B | May 15, 2025 | ▲ 978.9K |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 3.88M | 4.65% | 4.65% | $46.12B | May 15, 2025 | — held |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 3.19M | 3.82% | 3.82% | $37.88B | May 13, 2025 | ▼ 397.9K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 2.91M | 3.49% | 3.49% | $34.61B | May 14, 2025 | ▼ 94.0K |
STATE STREET CORP pharmaceutical preparations | 2.86M | 3.42% | 3.42% | $33.99B | May 15, 2025 | ▲ 58.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
21
Increased
+7.21M shares2
New Positions
first time holders20
Decreased
−3.15M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.07M
+7.21M / −3.15M
Net new holders
+3
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NRIX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
18
Buy transactions
19
Sell transactions
0.95
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Ring Christine Chief Legal Officer | Jun 2, 2026 | Sale | 8,148 | $16.60 | $135.3K | 13.6K | Form 4 ↗ |
Silva Paul M director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Saltzman Edward C director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Reinsdorf Judith A director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Lacey David L. director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Kapur Anil director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
DANSEY ROGER D director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Baynes Roy D. director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
GREGORY JULIA P director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
van Houte Hans Chief Financial Officer | May 5, 2026 | Sale | 13,473 | $16.58 | $223.3K | 38.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Nurix Therapeutics, Inc. (NRIX) is primarily owned by institutional investors, who hold approximately 97.6% of total shares outstanding. Company insiders own approximately 0.01%, while retail and public investors account for the remaining 2.37%.
The largest institutional shareholder of Nurix Therapeutics, Inc. is FMR LLC, holding approximately 10.33 million shares — equal to 12.36% of outstanding shares — as of March 31, 2025.
A total of 172 institutional investors currently hold NRIX stock, with a combined institutional value of approximately $1.01 billion as of the most recent 13F filing period.
Frequently asked questions
NRIX ownershipNurix Therapeutics, Inc. (NRIX) is primarily owned by institutional investors, who hold approximately 97.6% of shares. The largest shareholder is FMR LLC with a 12.36% stake. Company insiders hold 0.01%. Data sourced from SEC Form 13F as of March 31, 2025.